M&T Bank
PTGX icon

M&T Bank’s Protagonist Therapeutics PTGX Stock Holding History

M&T Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Buy
3,850
+97
+3% +$8.59K ﹤0.01% 1218
2025
Q4 		$328K Buy
+3,753
New +$307K ﹤0.01% 1349

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

M&T Bank's PTGX Position: Q1 2026 in Review

M&T Bank increased its Protagonist Therapeutics (PTGX) stake by 2.6% in Q1 2026, buying an estimated $8.59K and bringing the position to 3,850 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #1218.

M&T Bank first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • M&T Bank held 3,850 shares of Protagonist Therapeutics worth $406K as of Q1 2026.
  • M&T Bank bought 97 Protagonist Therapeutics shares in Q1 2026, an estimated $8.59K.
  • Protagonist Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q1 2026, its #1218 holding.
  • M&T Bank first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.